Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy

Transplantation

Volumn 75, Issue 3, 2003, Pages 309-315

  Yang, Chul Woo ^a   Ahn, Hee Jong ^a   Kim, Wan Young ^a,b   Li, Can ^a,c   Jung, Ju Young ^b   Yoon, Sun Ae ^a   Kim, Yong Soo ^a   Cha, Jung Ho ^b   Kim, Jin ^b   Bang, Byung Kee ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c YANBIAN UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; CYCLOSPORIN A; DRUG VEHICLE; LOSARTAN; MESSENGER RNA; MYCOPHENOLIC ACID; OLIVE OIL; OSTEOPONTIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DISEASE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FIBROSING ALVEOLITIS; INTERSTITIAL NEPHRITIS; KIDNEY ARTERY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; MALE; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PARAMETER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZATION; RAT; SODIUM RESTRICTION; STATISTICAL ANALYSIS;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIOLES; BLOOD PRESSURE; BODY WEIGHT; CHRONIC DISEASE; CYCLOSPORINE; DRUG SYNERGISM; FIBROSIS; GENE EXPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; LOSARTAN; MACROPHAGES; MALE; MYCOPHENOLIC ACID; OSTEOPONTIN; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SIALOGLYCOPROTEINS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 0037442098     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000045034.48833.51     Document Type: Article

References (28)

1. Bennett WM, DeMattos A, Meyer MM, et al. Chronic cyclosporine nephrotoxicity: the Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 1089.
2. Myers BD, Ross J, Newton L, et al. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 600.
3. Mourad G, Vela C, Ribstein J, et al. Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy. Transplantation 1998; 65: 661.
4. Campistol JM, Sacks SH. Mechanisms of nephrotoxicity. Transplantation 2000; 69: S5.
5. Ziai F, Nagano H, Kusaka M, et al. Renal allograft protection with losartan in Fisher-Lewis rats: hemodynamics, macrophages, and cytokines. Kidney Int 2000; 57: 2618.
6. Pichler RH, Franceschini N, Young BA, et al. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995; 6: 1186.
7. Allison AC, Eugui EM. Mycophenolate mofetil: a rationally designed immunosuppressive drug. Clin Transplant 1993; 7: 96.
8. Heemann U, Azuma H, Schmid C, et al. Effects of mycophenolic acid mofetil on acute rejection of kidney allografts in rats. Clin Nephrol 1996; 45: 355.
9. Wang W, Mo S, Chan L. Mycophenolic acid inhibits PDGF-induced osteopontin expression in rat mesangial cells. Transplant Proc 1999; 31: 1176.
10. Nadeau KC, Azuma H, Tilney NL. Sequential cytokine expression in renal allografts in rats immunosuppressed with maintenance cyclosporine or mycophenolate mofetil. Transplantation 1996; 62: 1363.
11. Fujihara CK, Malheiros DM, Zatz R, et al. Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 1998; 54: 1510.
12. Romero F, Rodriguez-Iturbe B, Parra G, et al. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 1999; 55: 945.
13. Valentin JF, Bruiin JA, Paul LC. Donor treatment with mycophenolate mofetil: protection against ischemia-reperfusion injury in the rat. Transplantation 2000; 69: 344.
14. Wong G, Price WA, Chiu AT, et al. Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Hypertension 1990; 15: 459.
15. Giachelli C, Bae N, Lombardi D, et al. Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein I, 2aR). Biochem Biophys Res Commun 1991; 177: 867.
16. Yang CW, Ahn HJ, Kim WY, et al. Influence of renin-angiotensin system on epidermal growth factor expression in normal and cyclosporine-treated rat kidney. Kidney Int 2001; 60: 847.
17. Burdmann EA, Andoh TF, Nast CC, et al. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 1995; 269: F491.
18. Shihab FS, Andoh TF, Tanner AM, et al. Role of transforming growth factor-beta1 in experimental chronic cyclosporine nephropathy. Kidney Int 1996; 49: 1141.
19. Elzinga LW, Rosen S, Bennett WM. Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporin nephropathy: role of sodium intake. J Am Soc Nephrol 1993; 4: 214.
20. Lui SL, Lui SL, Chan LY, et al. Effect of mycophenolate mofetil on nitric oxide production and inducible nitric oxide synthase gene expression during renal ischaemia-reperfusion injury. Nephrol Dial Transplant 2001; 16: 1577.
21. Hauser IA, Renders L, Radeke HH, et al. Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 1999; 14: 58.
22. Young BA, Burdmann EA, Johnson RJ, et al. Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int 1995; 48: 439.
23. Rodriguez-Iturbe B, Pons H, Quiroz Y, et al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int 2001; 59: 2222.
24. Quiroz Y, Pons H, Gordon KL, et al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol Renal Physiol 2001; 281: F38.
25. Yang CW, Ahn HJ, Kim WY, et al. Effect of cyclosporine withdrawal and supplementary mycophenolate mofetil treatment on the progression of chronic cyclosporine nephrotoxicity. Kidney Int 2002; 62: 20.
26. Noris M, Azzollini N, Pezzotta A, et al. Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft. J Am Soc Nephrol 2001; 12: 1937.
27. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000; 47: 85.
28. Fujihara CK, De Lourdes Noronha I, Malheiros E, et al. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 2000; 11: 283.